IPSEY News and Press, Ipsen SA ADR From 09/10/23

2023-09-10 06:05:05 ET Summary Positive results achieved in phase 3 RESPONSE study, which used seladelpar for the treatment of patients with primary biliary cholangitis. Positive results of the phase 3 RESPONSE study leads to additional data at an upcoming medical meeting and poss...

2023-09-07 07:56:40 ET More on CymaBay Seeking Alpha’s Quant Rating on CymaBay Therapeutics Historical earnings data for CymaBay Therapeutics Financial information for CymaBay Therapeutics CymaBay Therapeutics, Inc. ( CBAY ) Q2 2023 Earnings Call...

2023-08-21 07:29:59 ET More on Exelixis Exelixis: Stock Likely To Break Out Of 5-Year Inertia Exelixis: Thriving Investment Opportunity In The Evolving World Of Oncology Exelixis, Teva settle patent dispute over cancer drug Cabometyx Exelixis a new overweight...

2023-08-16 17:21:17 ET More on Ipsen Ipsen bone disorder therapy rejected in EU Ipsen wins FDA AdCom nod for bone disease therapy Mirum falls as FDA expands label for Ipsen’s liver disease therapy For further details see: Ipsen wins FDA approval of...

2023-08-11 17:59:00 ET Summary Hutchmed (China) Limited, a Chinese biopharma company, has experienced fluctuations in its stock price but has potential for improvement. The company acts as a liaison between the healthcare systems of China and the U.S., working to get its products ...

2023-07-27 08:47:25 ET Ipsen S.A. press release ( OTCPK:IPSEY ): 1H GAAP EPS of €2.35. Revenue of €1.54B (+7.7% Y/Y). For further details see: Ipsen S.A. GAAP EPS of €2.35, revenue of €1.54B

2023-07-13 08:04:34 ET Intercept Pharmaceuticals ( NASDAQ: ICPT ) gained ~10% pre-market Thursday after H.C. Wainwright upgraded it to Buy from Sell, citing a novel drug combination the company is developing for an autoimmune disease called primary biliary cholangitis (PBC). ...

2023-07-10 19:36:22 ET Summary A PDUFA date of September 9, 2023 has been established for review of Motixafortide for Autologous Transplantation in Multiple Myeloma. Results from a phase 2 Columbia University investigator study, using Motixafortide in combination with LIBTAYO + SO...

2023-06-30 06:58:14 ET French biotech Genfit S.A. ( NASDAQ: GNFT ) added ~23% pre-market Friday after the company and its partner Ipsen ( OTCPK:IPSEY ) ( OTCPK:IPSEF ) announced that a Phase 3 trial for elafibranor targeted at the rare liver disease primary biliary chola...

2023-06-14 13:32:05 ET The FDA’s decision to expand the label for liver disease therapy Bylvay from French pharma Ipsen ( OTCPK:IPSEY ) ( OTCPK:IPSEF ) pressured the U.S. biotech Mirum Pharma ( NASDAQ: MIRM ) – which markets a rival therapy – on Wednesda...